Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Health Coverage for OTC-Like Drugs Up for Review Yet Again
November 13, 2012
- Hodanren Asks MHLW to Disclose Discussions by Members of Drug Pricing Organization
November 13, 2012
- Zoledronic Acid, Sildenafil Subject to Pilot Study on Generic RMPs
November 12, 2012
- Drug Makers Invited to Join in Intractable Disease Drug Discovery Research Using iPS Cells from This Fiscal Year
November 8, 2012
- 15 Pharmacies Wrongly Claimed 41.6 Million Yen in Dispensing Fees Over 6 Year Period: Board of Audit
November 7, 2012
- Kampo Should Be Excluded from Denominator to Figure out Generic Volume Share
November 5, 2012
- CSIMC Expert Subcommittee Supports Continuation of Different NHI Prices for Long-Listed Drugs and Generics
November 2, 2012
- PAFSC’s 2nd Committee Recommends Additional Indication for Biosimilar Gran
November 2, 2012
- Number of Diseases Eligible for Medical Aid Would Increase to Over 300 Under New Proposal
November 1, 2012
- RMP to Be Made Available through the Internet During Review Stage: Director Tawaragi of PFSB
October 30, 2012
- MHLW Earmarks 200 Mil. Yen for Drug Quality Assurance and Development of New Vaccine Quality Test Methods as Part of Emergency Economic Measures
October 30, 2012
- Japan Adopts Emergency Economic Package, 3.8 Billion Yen Front-Loaded for iPS Research, Drug Discovery Support
October 30, 2012
- PAFSC’s 1st Committee Recommends Approval for Pfizer’s OAB Drug Toviaz
October 29, 2012
- DPJ Vice President Sengoku Says JMA “Paranoid” over TPP Concerns
October 29, 2012
- Keidanren, JCCI Call for Expansion of R&D Tax Break System at Tax Commission Hearings
October 29, 2012
- Number of Pharmacies in Japan Rises to 54,780 as of FY2011 End: MHLW
October 29, 2012
- MHLW Unveils Action Plan for 5-Year Clinical Trial Activation Plan
October 26, 2012
- MHLW to Initially Limit Number of Stores to Offer Epadel OTC
October 26, 2012
- US Paperwork Reduction Act Will Not Affect ICH PBRER Guidelines: MHLW
October 26, 2012
- BBPD to Seek Reductions in Market Prices of Domestic Blood Products: New BBPD Director Kato
October 26, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…